Recruitment of tetraspanin TSP-15 to epidermal wounds promotes plasma membrane repair in C. elegans

1. Download : Download high-res image (186KB)
2. Download : Download full-size image

     

Hydrogen gas inhalation protects against cutaneous ischaemia/reperfusion injury in a mouse model of pressure ulcer

Pressure ulcer formation depends on various factors among which repetitive ischaemia/reperfusion(I/R) injury plays a vital role. Molecular hydrogen (H₂) was reported to have protective effects on I/R injuries of various internal organs. In this study, we investigated the effects of H₂ inhalation on pressure ulcer and the underlying mechanisms. H₂ inhalation significantly reduced wound area, 8‐oxo‐dG level (oxidative DNA damage) and cell apoptosis rates in skin lesions. H₂ remarkably decreased ROS accumulation and enhanced antioxidant enzymes activities by up‐regulating expression of Nrf2 and its downstream components in wound tissue and/or H₂O₂‐treated endothelia. Meanwhile, H₂ inhibited the overexpression of MCP‐1, E‐selectin, P‐selectin and ICAM‐1 in oxidant‐induced endothelia and reduced inflammatory cells infiltration and proinflammatory cytokines (TNF‐α, IL‐1, IL‐6 and IL‐8) production in the wound. Furthermore, H₂ promoted the expression of pro‐healing factors (IL‐22, TGF‐β, VEGF and IGF1) and inhibited the production of MMP9 in wound tissue in parallel with acceleration of cutaneous collagen synthesis. Taken together, these data indicated that H₂ inhalation suppressed the formation of pressure ulcer in a mouse model. Molecular hydrogen has potentials as a novel and alternative therapy for severe pressure ulcer. The therapeutic effects of molecular hydrogen might be related to its antioxidant, anti‐inflammatory, pro‐healing actions.     

MSC-exosome: A novel cell-free therapy for cutaneous regeneration

Cutaneous regeneration is a dynamic and complex process that requires a series of coordinated interactions involving epidermal cells, dermal cells, growth factors, the extracellular matrix (ECM), nerves and blood vessels at a damaged site. Mesenchymal stromal cells (MSCs) have been reported to participate in all afore-mentioned stages. Exosomes are one of the key secretory products of MSCs, resembling the effect of parental MSCs. They can shuttle various proteins, messenger RNA (mRNA) and microRNAs (miRNAs) to modulate the activity of recipient cells, and play important roles in cutaneous wound healing. Compared with MSCs, exosomes are more convenient to store and transport. Moreover, they avoid many risks associated with cell transplantation. Therefore, MSC-exosome–mediated therapy may be more safe and efficient. In this review, we summarize the latest studies and observations on the role of MSC-exosome in the acute and chronic wound model and provide a comprehensive understanding of the role of exosomes in wound healing. This review can assist investigators in exploring new therapeutic strategies for enhancing the efficacy of MSC-exosome for cutaneous repair and regeneration.     

Human mesenchymal stromal cells do not promote recurrence of soft tissue sarcomas in mouse xenografts after radiation and surgery

Background. Mesenchymal stromal cells (MSCs) promote wound healing, including after radiotherapy (RT) and surgery. The use of MSCs in regenerative medicine in the context of malignancy, such as to enhance wound healing post-RT/surgery in patients with soft tissue sarcomas (STSs), requires safety validation. The aim of this study was to determine the effects of human MSCs on STS growth in vitro and local recurrence and metastasis in vivo. Methods. Human primary STS and HT-1080 fibrosarcoma lines were transduced to express luciferase/eGFP (enhanced green fluorescent protein). Sarcoma cells were co-cultured or co-injected with bone marrow–derived MSCs for growth studies. Xenograft tumor models were established with STS lines in NOD/SCID/γ_c^null mice. To emulate a clinical scenario, subcutaneous tumors were treated with RT/surgery prior to MSC injection into the tumor bed. Local and distant tumor recurrence was studied using histology and bioluminescence imaging. Results. MSCs did not promote STS proliferation upon co-culture in vitro, which was consistent among MSCs from different donors. Co-injection of MSCs with sarcoma cells in mice exhibited no significant tumor-stimulating effect, compared with control mice injected with sarcoma cells alone. MSC administration after RT/surgery had no effect on local recurrence or metastasis of STS. Discussion. These studies are important for the establishment of a safety profile for MSC administration in patients with STS. Our data suggest that MSCs are safe in STS management after standard of care RT/surgery, which can be further investigated in early-phase clinical trials to also determine the efficacy of MSCs in reducing morbidity and to mitigate wound complications in these patients.     

Jmjd3和Ezh2拮抗调节小鼠骨折愈合

目的:探讨Jmjd3和Ezh2在小鼠骨折愈合过程中的作用。方法:以软骨细胞条件性基因敲除8-10周龄小鼠为研究对象,按基因型随机分为6组,每组5只:其中实验组基因型为Jmjd3~(fl/fl)/Col2a1-Cre ~(ERT2),Ezh2~(fl/fl)/Col2a1-Cre ~(ERT2)或Jmjd~(3fl/fl)/Ezh2~(fl/fl)/Col2a1-Cre ~(ERT2);对照组基因型为Jmjd3~(fl/fl),Ezh2~(fl/fl)或Jmjd3~(fl/fl)/Ezh2~(fl/fl)。建立骨髓腔中插入固定针的稳定性胫骨骨折模型,于骨折术后3天、5天和7天腹腔注射Tamoxifen 3 mg/次/天。各组于术后3W处死,并于骨折部位取材行X线片及组织学检查。结果:通过连续的X线影像学及HE组织切片观察,骨折术后3周是判断小鼠骨折愈合情况的最佳时间点。X线片发现骨折术后3W时软骨细胞内Jmjd3被敲除小鼠的骨折线较对照组明显且骨化骨痂大小和密度均较低,HE切片显示骨化骨痂面积显著低于对照组,而软骨骨痂面积高于对照组;相反,X线片发现Ezh2被敲除小鼠的骨痂面积明显大于对照组,且密度高于对照组,HE组织切片显示Ezh2被敲除的小鼠的骨化骨痂的钙化程度更高,骨小梁更粗更密集。最后,X线片和HE切片均没有发现软骨细胞Jmjd3和Ezh2同时被敲除的小鼠与对照小鼠之间存在明显差异。结论:以软骨细胞特异基因敲除小鼠为基础,我们首次发现Jmjd3具有促进骨折愈合的作用,而Ezh2具有抑制骨折愈合的作用;并且发现Jmjd3和Ezh2对抗调节小鼠的骨折愈合过程,这些发现为骨折愈合治疗提供了新的分子实验基础。